We report the case of a 47-year-old woman with Stage VI gastric cancer accompanied by p2 grade dissemination which responded to chemotherapy using TS-1. Treatment of the patient with daily oral administration of 80 mg TS-1 for 2 cycles resulted in partial regression in the size of the primary lesion. Side effects were only seen after administration of 1 month, as mild pigmentation easily controlled by white vaseline ointment. After 6 cycles of administration, the effect on the gastric mucosal lesion decreased, and the wall thickness and stenosis of the antrum were increased. The patient has been administered 10 cycles of chemotherapy with no myelosupression, and maintains a good quality of life.

Download full-text PDF

Source

Publication Analysis

Top Keywords

gastric cancer
8
case gastric
4
cancer responding
4
responding ts-1
4
ts-1 long
4
long survival
4
survival months]
4
months] report
4
report case
4
case 47-year-old
4

Similar Publications

Purpose: The aim of this study was to identify prognostic factors influencing overall survival (OS) in patients with gastric cancer treated with adjuvant chemoradiotherapy (CRT) and to develop a predictive model.

Methods: We retrospectively evaluated 245 non-metastatic gastric cancer patients who received adjuvant CRT or radiotherapy from 2010 to 2020. Survival analyses were performed using the Kaplan-Meier method.

View Article and Find Full Text PDF

Lynch Syndrome: Similarities and Differences of Recommendations in Published Guidelines.

J Gastroenterol Hepatol

January 2025

Department of Gastroenterology and Hepatology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Background: In this review, we aimed to compare the recommendations for Lynch syndrome (LS).

Methods: We compared the LS's guidelines of different medical societies, including recommendations for cancer surveillance, aspirin treatment, and universal screening.

Results: Most guidelines for LS patients recommend intervals of 1-2 years for performing colonoscopy, though there is disagreement regarding the age to begin CRC screening (dependent on status as a MLH1/MSH2 or MSH6/PMS2 carrier).

View Article and Find Full Text PDF

The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with a strategy to ensure the safety of patients.

Mol Ther

January 2025

Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Shenzhen Key Laboratory, Hematology Institution of Shenzhen University, Shenzhen University Health Science Center, Shenzhen University, Shenzhen, China; Shenzhen University-Haoshi Cell Therapy Institute, Shenzhen, China. Electronic address:

Pancreatic cancer (PC) is one of the most lethal digestive system tumors. Claudin18.2 is highly expressed in PC tissue and could serve as a suitable target for CAR-T therapy.

View Article and Find Full Text PDF

Evaluation of Plasma microRNA-222 as a Biomarker for Gastric Cancer.

J Clin Med

December 2024

Department of Surgery, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura 285-8741, Chiba, Japan.

The dysregulation of microRNAs (miRNAs) has been detected in patients with gastric cancer (GC), which inspired the use of miRNAs as a novel biomarker for GC. In this study, we investigated the previously reported miRNA dysfunction in cancer tissues as a potential plasma biomarker for GC using quantitative reverse transcriptase polymerase chain reaction (RT-PCR). The published miRNA abnormalities were searched in the microRNA Cancer Association Database.

View Article and Find Full Text PDF

Background/objectives: Gastric intestinal metaplasia (GIM) is considered an irreversible preneoplastic precursor for gastric adenocarcinoma in adults. However, its significance in children and the long-term outcome remain poorly understood.

Methods: All children diagnosed with GIM between 2000 and 2020 were identified at a large tertiary referral centre.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!